youtube_live
Q2 2027 earnings • in 4 days
See detailschevron_right
RDY:NYSE
Dr Reddy's Laboratories Ltd
$13.06
arrow_upward
+0.04%(+0.0050) 1D
Oct 19, 2:31:59 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RDY...
Open
$13.05
High
$13.12
Low
$13.02
Mkt. cap
10.80B
Avg. vol.
3.10M
Volume
643.78K
Dividend
0.64%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
31.23
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.42
Beta
0.30
Shares outstanding
834.64M
No. of employees
28K
Open
$13.05
High
$13.12
Low
$13.02
Mkt. cap
10.80B
Avg. vol.
3.10M
Volume
643.78K
Dividend
0.64%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
31.23
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.42
Beta
0.30
Shares outstanding
834.64M
No. of employees
28K
News stories
From web sources and news partners
Investing.com India
·
4 hours ago
Dr. Reddy’s Labs ADR bulls stretched near $13.10: Live levels By Investing.com
ad-hoc-news.de
·
4 hours ago
Dr Reddy stock: Dr Reddy sets October 23 results. P/ E is 31.29 for Dr Reddy stock
ad-hoc-news.de
·
10 hours ago
Dr Reddy reported three FDA observations before Dr Reddy stock results
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Websitedrreddys.com
Analyst ratings
Based on 2 analysts giving stock ratings to RDY in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RDY in the last 3 months.
Highest
Current $13.06
$14.80 (+13.28%)
Average
$14.80 (+13.28%)
Lowest
$14.80 (+13.28%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Tausif Shaikh Exane BNP Paribas | Buy | Upgraded | $14.80 | +13.3% | 10/12/2026 |
Neha Manpuria Bank of America Securities | Buy | Maintained | - | - | 10/01/2026 |
Unknown Analyst Citi | Sell | Maintained | - | - | 04/23/2026 |
Next call in 4 days
Fri, Oct 23, 4:00 PM
Fiscal period
Q2 2027
- Normalized EPS / Est. (INR)
- GAAP EPS / Est. (INR)
- / ₹8.95
Revenue / Est. (INR)
- / 85.94B
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in INR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 88.05B | 87.27B | 75.16B | 80.70B |
Cost of goods sold | 39.91B | 40.46B | 41.47B | 43.16B |
Cost of revenue | 39.91B | 40.46B | 41.47B | 43.16B |
Research and development expenses | 6.20B | 6.15B | 5.46B | 5.77B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 26.44B | 26.92B | 27.76B | 28.82B |
Operating expense | 31.90B | 32.48B | 32.53B | 34.11B |
Total operating expenses | 71.81B | 72.94B | 74.00B | 77.27B |
Operating income | 16.24B | 14.33B | 1.16B | 3.43B |
Other non operating income | 1.28B | 570.00M | 512.00M | - |
EBT including unusual items | 18.35B | 15.43B | 1.99B | 5.53B |
EBT excluding unusual items | 17.81B | 15.52B | 1.82B | 4.09B |
Income tax expense | 4.08B | 3.53B | -214.00M | 1.18B |
Effective tax rate | 22.24% | 22.90% | -10.75% | 21.32% |
Other operating expenses | -740.00M | -591.00M | -693.00M | -477.00M |
Net income | 14.37B | 12.10B | 2.20B | 4.44B |
Net profit margin | 16.32% | 13.86% | 2.93% | 5.50% |
Earnings per share | 17.87 | 14.77 | 5.74 | 5.33 |
Interest and investment income | 912.00M | 796.00M | 890.00M | 999.00M |
Interest expense | -907.00M | -944.00M | -1.06B | -1.26B |
Net interest expenses | 5.00M | -148.00M | -167.00M | -256.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 21.29B | 19.54B | 5.03B | 8.80B |
Gain or loss from assets sale | -308.00M | -179.00M | -2.10B | -368.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1